Nationwide Fund Advisors Prothena Corp Public LTD CO Transaction History

Nationwide Fund Advisors

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2017 Feb 01, 2018	SELL	$35.44 - $63.76 $720,211 - $1.3 Million	-20,322 Closed	0 $0
Q3 2017 Oct 23, 2017	SELL	$53.83 - $67.75 $1.41 Million - $1.77 Million	-26,182 Reduced 56.3%	20,322 $1.32 Million
Q2 2017 Aug 10, 2017	BUY	N/A	46,504	46,504 $2.52 Million

187

45.4M

119K

144K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $1.11B
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Nationwide Fund Advisors, based on Form 13F filings with the SEC.

Stay updated on Nationwide Fund Advisors with notifications on news.